Dysadherin: A new player in cancer progression

Cancer Letters

Volumn 255, Issue 2, 2007, Pages 161-169

  Nam, Jeong Seok ^a   Hirohashi, Setsuo ^b   Wakefield, Lalage M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Breast cancer; Chemokine (C C motif) ligand 2; Dysadherin; E cadherin; Metastasis

Indexed keywords

CHEMOKINE; DYSADHERIN; UVOMORULIN;

CANCER GROWTH; CELL ADHESION; HUMAN; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; SHORT SURVEY; TUMOR CELL; UPREGULATION;

EID: 34547937490     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.02.018     Document Type: Review

References (39)

1. Ino Y., Gotoh M., Sakamoto M., Tsukagoshi K., and Hirohashi S. Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasis. Proc. Natl. Acad Sci. USA 99 (2002) 365-370
2. Lubarski I., Pihakaski-Maunsbach K., Karlish S.J., Maunsbach A.B., and Garty H. Interaction with the Na,K-ATPase and tissue distribution of FXYD5 (related to ion channel). J. Biol. Chem. 280 (2005) 37717-37724
3. Geering K. FXYD proteins: new regulators of Na-K-ATPase. Am. J. Physiol. Renal Physiol. 290 (2006) F241-F250
4. Tsuiji H., Takasaki S., Sakamoto M., Irimura T., and Hirohashi S. Aberrant O-glycosylation inhibits stable expression of dysadherin, a carcinoma-associated antigen, and facilitates cell-cell adhesion. Glycobiology 13 (2003) 521-527
5. Fu X., and Kamps M.P. E2a-Pbx1 induces aberrant expression of tissue-specific and developmentally regulated genes when expressed in NIH 3T3 fibroblasts. Mol. Cell Biol. 17 (1997) 1503-1512
6. Bild A.H., Yao G., Chang J.T., Wang Q., Potti A., Chasse D., Joshi M.B., Harpole D., Lancaster J.M., Berchuck A., Olson Jr. J.A., Marks J.R., Dressman H.K., West M., and Nevins J.R. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439 (2006) 353-357
7. Robinson M., Jiang P., Cui J., Li J., Wang Y., Swaroop M., Madore S., Lawrence T.S., and Sun Y. Global genechip profiling to identify genes responsive to p53-induced growth arrest and apoptosis in human lung carcinoma cells. Cancer Biol. Ther. 2 (2003) 406-415
8. Shimamura T., Yasuda J., Ino Y., Gotoh M., Tsuchiya A., Nakajima A., Sakamoto M., Kanai Y., and Hirohashi S. Dysadherin expression facilitates cell motility and metastatic potential of human pancreatic cancer cells. Cancer Res. 64 (2004) 6989-6995
9. Nam J.S., Kang M.J., Suchar A.M., Shimamura T., Kohn E.A., Michalowska A.M., Jordan V.C., Hirohashi S., and Wakefield L.M. Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Res. 66 (2006) 7176-7184
10. Yanagihara K., Tanaka H., Takigahira M., Ino Y., Yamaguchi Y., Toge T., Sugano K., and Hirohashi S. Establishment of two cell lines from human gastric scirrhous carcinoma that possess the potential to metastasize spontaneously in nude mice. Cancer Sci. 95 (2004) 575-582
11. Hirohashi S., and Kanai Y. Cell adhesion system and human cancer morphogenesis. Cancer Sci. 94 (2003) 575-581
12. Conti I., and Rollins B.J. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin. Cancer Biol. 14 (2004) 149-154
13. Ueno T., Toi M., Saji H., Muta M., Bando H., Kuroi K., Koike M., Inadera H., and Matsushima K. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res. 6 (2000) 3282-3289
14. Saji H., Koike M., Yamori T., Saji S., Seiki M., Matsushima K., and Toi M. Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 92 (2001) 1085-1091
15. Ohta M., Kitadai Y., Tanaka S., Yoshihara M., Yasui W., Mukaida N., Haruma K., and Chayama K. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human gastric carcinomas. Int. J. Oncol. 22 (2003) 773-778
16. Salcedo R., Ponce M.L., Young H.A., Wasserman K., Ward J.M., Kleinman H.K., Oppenheim J.J., and Murphy W.J. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96 (2000) 34-40
17. Youngs S.J., Ali S.A., Taub D.D., and Rees R.C. Chemokines induce migrational responses in human breast carcinoma cell lines. Int. J. Cancer 71 (1997) 257-266
18. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am. J. Pathol. 153 (1998) 333-339
19. Shimamura T., Sakamoto M., Ino Y., Sato Y., Shimada K., Kosuge T., Sekihara H., and Hirohashi S. Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: relationship to E-cadherin expression. J. Clin. Oncol. 21 (2003) 659-667
20. Batistatou A., Charalabopoulos A.K., Scopa C.D., Nakanishi Y., Kappas A., Hirohashi S., Agnantis N.J., and Charalabopoulos K. Expression patterns of dysadherin and E-cadherin in lymph node metastases of colorectal carcinoma. Virchows Arch. 448 (2006) 763-767
21. Kyzas P.A., Stefanou D., Batistatou A., Agnantis N.J., Nakanishi Y., Hirohashi S., and Charalabopoulos K. Dysadherin expression in head and neck squamous cell carcinoma: association with lymphangiogenesis and prognostic significance. Am. J. Surg. Pathol. 30 (2006) 185-193
22. Batistatou A., Scopa C.D., Ravazoula P., Nakanishi Y., Peschos D., Agnantis N.J., Hirohashi S., and Charalabopoulos K.A. Involvement of dysadherin and E-cadherin in the development of testicular tumours. Br J. Cancer 93 (2005) 1382-1387
23. Tamura M., Ohta Y., Tsunezuka Y., Matsumoto I., Kawakami K., Oda M., and Watanabe G. Prognostic significance of dysadherin expression in patients with non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 130 (2005) 740-745
24. Nishizawa A., Nakanishi Y., Yoshimura K., Sasajima Y., Yamazaki N., Yamamoto A., Hanada K., Kanai Y., and Hirohashi S. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients. Cancer 103 (2005) 1693-1700
25. Wu D., Qiao Y., Kristensen G.B., Li S., Troen G., Holm R., Nesland J.M., and Suo Z. Prognostic significance of dysadherin expression in cervical squamous cell carcinoma. Pathol. Oncol. Res. 10 (2004) 212-218
26. Nakanishi Y., Akimoto S., Sato Y., Kanai Y., Sakamoto M., and Hirohashi S. Prognostic significance of dysadherin expression in tongue cancer: immunohistochemical analysis of 91 cases. Appl. Immunohistochem. Mol. Morphol. 12 (2004) 323-328
27. Shimada Y., Hashimoto Y., Kan T., Kawamura J., Okumura T., Soma T., Kondo K., Teratani N., Watanabe G., Ino Y., Sakamoto M., Hirohashi S., and Imamura M. Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma. Oncology 67 (2004) 73-80
28. Shimada Y., Yamasaki S., Hashimoto Y., Ito T., Kawamura J., Soma T., Ino Y., Nakanishi Y., Sakamoto M., Hirohashi S., and Imamura M. Clinical significance of dysadherin expression in gastric cancer patients. Clin. Cancer Res. 10 (2004) 2818-2823
29. Sato H., Ino Y., Miura A., Abe Y., Sakai H., Ito K., and Hirohashi S. Dysadherin: expression and clinical significance in thyroid carcinoma. J. Clin. Endocrinol. Metab. 88 (2003) 4407-4412
30. Wang Y., Klijn J.G., Zhang Y., Sieuwerts A.M., Look M.P., Yang F., Talantov D., Timmermans M., Meijer-van Gelder M.E., Yu J., Jatkoe T., Berns E.M., Atkins D., and Foekens J.A. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 (2005) 671-679
31. van 't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., Schreiber G.J., Kerkhoven R.M., Roberts C., Linsley P.S., Bernards R., and Friend S.H. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
32. Freije W.A., Castro-Vargas F.E., Fang Z., Horvath S., Cloughesy T., Liau L.M., Mischel P.S., and Nelson S.F. Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 64 (2004) 6503-6510
33. Asgharzadeh S., Pique-Regi R., Sposto R., Wang H., Yang Y., Shimada H., Matthay K., Buckley J., Ortega A., and Seeger R.C. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J. Natl. Cancer Inst. 98 (2006) 1193-1203
34. Sun L., Hui A.M., Su Q., Vortmeyer A., Kotliarov Y., Pastorino S., Passaniti A., Menon J., Walling J., Bailey R., Rosenblum M., Mikkelsen T., and Fine H.A. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 9 (2006) 287-300
35. Graudens E., Boulanger V., Mollard C., Mariage-Samson R., Barlet X., Gremy G., Couillault C., Lajemi M., Piatier-Tonneau D., Zaborski P., Eveno E., Auffray C., and Imbeaud S. Deciphering cellular states of innate tumor drug responses. Genome Biol. 7 (2006) R19
36. Crambert G., and Geering K. FXYD proteins: new tissue-specific regulators of the ubiquitous Na,K-ATPase. Sci STKE 2003 (2003) RE1
37. Kometiani P., Li J., Gnudi L., Kahn B.B., Askari A., and Xie Z. Multiple signal transduction pathways link Na+/K+-ATPase to growth-related genes in cardiac myocytes. The roles of Ras and mitogen-activated protein kinases. J. Biol. Chem. 273 (1998) 15249-15256
38. Mohammadi K., Kometiani P., Xie Z., and Askari A. Role of protein kinase C in the signal pathways that link Na+/K+-ATPase to ERK1/2. J. Biol. Chem. 276 (2001) 42050-42056
39. Kaplan R.N., Rafii S., and Lyden D. Preparing the "Soil": the pre-metastatic niche. Cancer Res. 66 (2006) 11089-11093